Reimagining the future of Huntington’s disease
SOPHIA Huntington’s Disease Community Advocate
Press Releases
Subscribe to receive breaking news alerts about uniQure.
Subscribe-
-
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
-
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease